BioSpace· Angela Gabriel·· 4 hours agoPickScore62
As H-1B visa changes keep coming, biopharmas adjust hiring approach
In brief
Changes to H-1B visa fees and selection rules are leading U.S. biopharmas to cut overseas hiring and turn to candidates already authorized to work in the United States. USCIS announced in May that eligible registrations fell 38.5%, from 343,981 in fiscal year 2026 to 211,600 in fiscal year 2027. Two federal judges have each blocked the $100,000 new-petition fee, but companies had already reduced lottery participation over cost concerns.
Why it matters
The article compares large pharma and startups in bearing the $100,000 fee and shows the narrowed hiring pool's impact on biopharma R&D roles.
Source: BioSpace